IRS2 and metabolic dysfunction-associated steatotic liver disease: Molecular therapies balancing glycogen metabolism and insulin resistance: An antihyperglycemic agent, metformin, may be beneficial in improving insulin sensitivity and restoring hepatic insulin receptor substrate-2 (IRS2)/phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways in models of non-alcoholic fatty liver disease (NAFLD) and cirrhosis [140].